Author

Manuel López‐López

Universidad de HuelvaORCID 0000-0001-9060-9554Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Arántzazu AlfrancaiD· 1 shared Enrique Martín‐GayoiD· 1 shared Francisco Sánchez‐MadridiD· 1 shared Ignacio de los SantosiD· 1 shared Ildefonso Sánchez‐CerrilloiD· 1 shared Ilya TsukaloviD· 1 shared Jesus Pino-Platas· 1 shared José Antonio Lebrón-Romero· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Arántzazu AlfrancaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

IFI16/AIM2 inflammasomes control Gal-9 and PVR in myeloid cells from PWH and their targeting improves immunotherapy against HIV-1

Marta Calvet‐Mirabent, Ilya Tsukalov, Ildefonso Sánchez‐Cerrillo, Jesus Pino-Platas, Paul Nicholas Holmes-Anton, María Agudo-Lera, Olga Popova, Raquel González, Lucio Jesus García-Fraile, José Antonio Lebrón-Romero, Manuel López‐López, Sergio Serrano-Villar, Santiago Moreno, Pilar López‐Cornejo, Francisco Sánchez‐Madrid, , Enrique Martín‐Gayo

The paper shows that inhibiting IFI16 and AIM2 in myeloid cells from HIV-1 patients reduces Gal-9 and PVR, enhancing CD8+ T-cell responses against HIV-1.

bioRxiv · Jan 28, 2026 · PreprintImmunology